Balancing Early Intervention in Smoldering Multiple Myeloma

In this segment, Dr. Sagar Lonial asks the panel to discuss the potential risks and benefits of early intervention in smoldering multiple myeloma, particularly given that many patients remain asymptomatic for extended periods. Dr. Vincent Rajkumar emphasizes that while emerging trial data suggest early treatment may delay progression in selected high-risk patients, clinicians must remain cautious about overtreatment. He notes that treatment-related toxicity, long-term therapy exposure, and the impact on quality of life are important considerations when treating patients who do not yet have symptomatic disease. Dr. Saad Usmani adds that identifying the appropriate patient population is critical. Patients with clearly defined high-risk disease and biological features associated with a greater likelihood of progression may be more appropriate candidates for early therapy. However, the panel highlights that uncertainties remain regarding long-term outcomes and optimal patient selection, reinforcing the importance of individualized decision-making when managing smoldering multiple myeloma.